neoantigen vaccine + specific lymphocytes + anti-PD1 antibody

This combination therapy is an experimental immunotherapy regimen being evaluated for the treatment of advanced or unresectable sarcomas, including osteosarcoma and soft tissue sarcoma. It consists of three distinct components: **SarcVac**, a personalized tumor neoantigen vaccine; **tumor-specific lymphocytes (TSLs)**, which are autologous immune cells expanded ex vivo and reinfused into the patient; and an **anti-PD1 antibody**, a checkpoint inhibitor. The vaccine is designed to prime the patient's immune system to recognize unique mutations (neoantigens) present on their specific tumor cells. The reinfused lymphocytes provide a robust population of effector cells to directly attack the tumor, while the PD-1 antibody prevents the tumor from evading the immune response by blocking the PD-1/PD-L1 inhibitory pathway. This triple combination aims to overcome the immunosuppressive microenvironment of advanced sarcomas and enhance anti-tumor efficacy in patients who have failed standard treatments.

Other names

SarcVac + tumor-specific lymphocytes + anti-PD1 antibodyNeoantigen vaccine + specific lymphocytes + anti-PD1 antibody